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Abstract
Background: The impact of sentinel lymph node biopsy on breast cancer mimicking ductal carcinoma in situ
(DCIS) is a matter of debate.
Methods: We studied the rate of occurrence of sentinel lymph node metastasis in 255 breast cancer patients with
pure DCIS showing no invasive components on routine pathological examination. We compared this to the rate of
occurrence in 177 patients with predominant intraductal-component (IDC) breast cancers containing invasive foci
equal to or less than 0.5 cm in size.
Results: Most of the clinical and pathological baseline characteristics were the same between the two groups.
However, peritumoral lymphatic permeation occurred less often in the pure DCIS group than in the IDC-
predominant invasive-lesion group (1.2% vs. 6.8%, p = 0.002). One patient (0.39%) with pure DCIS had two sentinel
lymph nodes positive for metastasis. This rate was significantly lower than that in patients with IDC-predominant
invasive lesions (6.2%; p < 0.001).
Conclusions: Because the rate of sentinel lymph node metastasis in pure DCIS is very low, sentinel lymph node
biopsy can safely be omitted.
Introduction
The technique of sentinel lymph node biopsy is used
worldwide as a surgical treatment for breast cancer
[1,2]. This procedure can accurately determine lymph
node metastasis [3,4]. Therefore morbid axillary dissec-
tion can be safely avoided when sentinel lymph nodes
are free from cancer [5,6].
The primary indication for sentinel lymph node biopsy
is invasive breast cancer, which has the potential of
metastasizing to the regional lymph nodes. On the other
hand, ductal carcinoma in situ (DCIS), which has no
invasive foci and is isolated from the interstitium, is not
believed to metastasize to the lymph nodes [7].
The determination of DCIS requires thorough exami-
nation of surgical materials, and very infrequent lymph
node metastases are observed in cases of DCIS that
show no invasive components on routine pathological
examination [8]. Furthermore, thorough examination of
the sentinel lymph nodes, which are the most likely
candidates for metastasis, is feasible. In these situations,
some investigators have argued that more than a few
cases of pure DCIS are accompanied by sentinel lymph
node metastasis, and the indications for sentinel lymph
node biopsy should be extended not only to cases with
invasive cancer, but also to those with pure DCIS [9].
However, others have argued that the incidence of
lymph node metastasis in pure DCIS is still very low,
and sentinel lymph node biopsy can be safely avoided in
these cases [10,11].
In this article, we studied the incidence of sentinel
lymph node metastasis in cases of pure DCIS. Further-
more, we compared this incidence with that of predomi-
nant intraductal-component (IDC) breast cancer with
invasive foci equal to or less than 0.5 cm in size. Then
we addressed the question of whether sentinel lymph
node biopsy is required in cases of pure DCIS.
Materials and methods
Patients and study design
We searched our surgical records from December 2006
to June 2008 for patients with a histology of pure DCIS
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cally as intraductal carcinoma without stromal invasion.
Inclusion criteria were as follows: curative surgical treat-
ment, performance of sentinel lymph node biopsy, and
no primary chemotherapy. Patients with metachronous
ipsilateral breast cancer were excluded. Furthermore, we
also searched for patients having an IDC-predominant
invasive lesion with the same profile as mentioned above.
IDC-predominant invasive lesions are those with a pre-
dominant IDC including one or more invasive foci, each
of which is not more than 0.5 cm in size.
Sentinel lymph node biopsy procedures
The method for sentinel lymph node biopsy using a radio-
active agent has been described elsewhere [12]. Briefly, the
radioactive tracer used was 1.5 mCi/ml of 99mTc-phytate
(Daiichi Radioisotope Laboratories, Ltd). The radioactive
tracer was injected into the intradermal space in the area
of the tumor and the retro-tumoral space. The tracer was
injected the day prior to surgery. In all cases, a lymphoscin-
tigraphy was obtained one hour after injection. Addition-
ally, vital dye (indigocarmine) was injected intradermally in
the peri-tumoral space just before surgery.
Histopathological procedures
Surgical materials from breast-conserving surgery were
sectioned at 0.5 cm intervals, and each section was
examined histologically. Surgical materials from mas-
tectomy were cut at several representative sections in
order to study the histopathological characteristics.
Sentinel lymph nodes were sectioned at 0.2 cm inter-
vals, and examinations were based on frozen sections in
most cases. Whether or not metastasis was present was
determined intraoperatively. Immunohistochemistry was
not used for analysis.
Statistical analysis
Frequency analysis was performed with Fisher’se x a c t
test. The difference in continuous variables was
evaluated using Student’s t-test. A significance level of
0.05 was used for statistical tests, and two-tailed tests
were applied. Calculations were performed using SPSS
16.0J for MAC (SPSS Japan Inc. Tokyo).
Results
Study population
From December 2006 to June 2008, 1919 surgical and
pathological records were registered. Among these, 1302
cases had sentinel lymph node biopsy and no primary
chemotherapy. In this cohort, 255 patients had pure
DCIS and 177 patients had an IDC-predominant inva-
sive lesion. During the same period, there were 42 cases
who had pure DCIS without sentinel lymph node
biopsy.
Patient characteristics
The patients’ characteristics are summarized in Table 1.
Most clinical and pathological baseline characteristics
showed no differences between the groups, including
age, estrogen receptor status, progesterone receptor sta-
tus, removed sentinel nodes, and surgical procedures.
However, the frequency of peritumoral lymphatic inva-
sion was higher in the IDC-predominant invasive-lesion
group than in the pure DCIS group (6.8% vs 1.2%: p =
0.002).
Patients with a positive sentinel node biopsy
One patient (0.39%) with pure DCIS had two sentinel
lymph nodes positive for metastasis, whereas 6.2% of the
patients with IDC-predominant invasive breast cancer
had positive sentinel lymph nodes. Therefore, the risk of
lymph node metastasis was significantly lower in the
pure DCIS group than in the IDC-predominant inva-
sive-lesion group, with a statistical significance of p <
0.001. The contingency table for the two groups is
shown in Table 2.
The major characteristics of node-positive patients
with pure DCIS or IDC-predominant invasive lesions
Table 1 Patient characteristics
Pure DCIS IDC predominant
invasive lesion
P-value
Mean Age (Range) 51.2(29-81) 51.9(27-86) *NS
Lymphatic permeation 3(1.2%) 12(6.8%) 0.002
Breast-conserving surgery 147(57.6%) 96(54.2%) NS
ER positive 194(74.9%) 133(76.8%) NS
negative 49(19.2%) 36(20.3%)
unknown 15(5.9%) 5(2.8%)
PgR positive 162(62.8%) 114(65.5%) NS
negative 81(31.4%) 55(31.6%)
unknown 15(5.8%) 5(2.8%)
Median number of removed nodes 2 2 NS
* NS; Not Specific
Tada et al. World Journal of Surgical Oncology 2010, 8:6
http://www.wjso.com/content/8/1/6
Page 2 of 5are summarized in Table 3. The patient with pure
DCIS had exclusive breast-conserving surgery, with a
slight positive surgical margin, and received radiation
therapy. Among the 11 patients who had an IDC-pre-
dominant invasive lesion with positive sentinel nodes,
4 patients had dislocation of cancer cells along the
biopsy scar.
Discussion
In this study, we found that the incidence of sentinel
lymph node metastasis in cases of pure DCIS was 0.39%.
This incidence was significantly lower than that in cases
of IDC-predominant invasive tumors (0.39% vs. 6.2%; p <
0.001). Therefore, our data suggest that sentinel lymph
node biopsy can be avoided in cases of pure DCIS.
Many publications concerning this issue have reported
only the rate of sentinel lymph node metastasis in pure
DCIS. We also calculated the rate of metastasis in IDC-
predominant invasive lesions. We believe that the rele-
vance of the metastasis rate in pure DCIS is supported
by comparing data concerning IDC-predominant inva-
sive lesions. Furthermore, we can estimate the rate of
sentinel lymph node metastasis in lesions mimicking
DCIS clinically.
The issue of pure DCIS and sentinel node biopsy is
associated with two major problems: one is that preo-
perative diagnosis of pure DCIS is difficult, and the
other is that postoperative definitive diagnosis of pure
DCIS is also difficult.
It is well known that preoperative diagnoses of DCIS
based on core needle biopsy are likely to be underesti-
mated. Rates of diagnosis range from 8.3% to 43.6%
[8,13,14]. Preoperative core needle biopsy does not guar-
antee that the entire lesion is without stromal invasion.
Furthermore, having less than 0.5 cm of stromal inva-
sion increases the incidence of sentinel lymph node
metastases [15,16]. As a result, many investigators insist
that sentinel lymph node biopsy should be encouraged
when DCIS-like tumors are large enough to be palpable
or when tumors require total mastectomy.
Table 2 Contingency table
Node-positive Node-negative Total
Pure DCIS 1 254 255
IDC predominant invasive lesion 11 166 177
12 420 432
p < 0.001
Table 3 Patients with positive nodes
Age Clinical
presentation
Histology Comedonecrosis Number of
positive nodes
Size of metastasis
in nodes
Lymphatic
permeation
Tumor
dislocation
1 46 US-detected
mass
Pure DCIS no 2 macro None none
2 48 Palpable mass IDC predominant
invasive lesion
no 1 micro Present yes
3 29 Palpable mass IDC predominant
invasive lesion
yes 1 micro Present yes
4 48 Nipple
discharge
IDC predominant
invasive lesion
no 1 micro None yes
5 54 Calcification on
MMG
IDC predominant
invasive lesion
no 1 ND None none
6 45 Palpable mass IDC predominant
invasive lesion
yes 2 macro None none
7 45 Calcification on
MMG
IDC predominant
invasive lesion
yes 1 micro None none
8 53 Palpable mass IDC predominant
invasive lesion
no 2 micro None none
9 54 Nipple
discharge
IDC predominant
invasive lesion
yes 1 macro None none
10 65 Palpable mass IDC predominant
invasive lesion
yes 1 macro None none
11 50 Palpable mass IDC predominant
invasive lesion
yes 1 macro None none
12 44 Palpable mass IDC predominant
invasive lesion
no 1 micro None yes
Abbreviations: US; Ultrasonography, MMG; Mammography, ND; Not Determined
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of pure DCIS does not always guarantee the absence of
lymph node metastasis. For many years, it has been
believed that DCIS is associated with the absence of
lymph node metastasis, that axillary dissection in DCIS
could be omitted, and that cases of lymph node metas-
tasis in DCIS are associated with invasive lesions that
are too small to be detected by the usual pathological
examination. However, in regular clinical practice the
detection of minimal stromal invasion is quite difficult.
Although sentinel lymph node biopsy is effective in
DCIS, we suggest that the application of sentinel node
biopsy to all DCIS cases should be avoided. That is
because, although sentinel node biopsy is less morbid
than axillary dissection, the procedure is not completely
free from morbidity [17].
We believe that Moore et al., who encouraged the use
of sentinel lymph node biopsy in pure DCIS, does not
argue that sentinel lymph node biopsy should be carried
out in all cases of pure DCIS [9]. In their literature, only
22% of all DCIS cases had sentinel lymph node biopsy.
The relatively high rate of axillary lymph node metas-
tases in their study can be associated with this selection.
I no u rs e r i e st h e r ew a so n ec a s eo fp u r eD C I Sw i t h
positive sentinel nodes. This case underwent a partial
mastectomy, and the surgical margin was slightly posi-
tive. Preoperative mammography, ultrasonography, and
MRI did not reveal any other abnormal lesions besides
the main tumor. However two sentinel nodes were posi-
tive for cancer and both metastases were larger than 2
mm. We think that this was an extremely rare case.
Although some authors encourage the preservation of
axillary nodes in cases of pure DCIS with positive senti-
nel nodes [10], an axillary dissection was performed in
this patient.
There is much debate concerning the association
between preoperative invasive procedures for diagnosis
and the likelihood of lymph node metastases. Displace-
ment of cancer cells around the main tumor is common,
and frequencies from 28% to 32% have been reported
previously [18,19]. Moreover, there is the possibility that
displacement can cause the migration of cancer cells to
lymph nodes[20]. However, the prognostic significance
of this migration is uncertain. Previous studies show
that large gauge needle biopsy does not affect the survi-
val risk [21,22]. Much more discussion and careful stu-
dies on this issue are necessary.
Our study has a considerable limitation. Our series
could miss cases of micrometastases or isolated tumor
cells (ICT) in sentinel nodes. In order to avoid this pro-
blem, the sentinel nodes should be sectioned at intervals
of at least 0.15 mm and immunohistochemistry should
be applied to sections at different levels. These analyses
should be performed on permanent paraffin sections.
Although the clinical significance of micrometastases
and ICT in DCIS has been unclear [23], the latest report
has shown that micrometastases or ICT may decrease
the probability of survival in invasive breast cancers [24].
In conclusion, we found that the incidence of sentinel
lymph node metastasis in cases of pure DCIS was
0.39%. This incidence was lower than that in IDC-pre-
dominant invasive lesions. Therefore, we believe that
sentinel lymph node biopsy in pure DCIS can be safely
omitted.
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